Author:
Pocaly M,Lagarde V,Etienne G,Ribeil J-A,Claverol S,Bonneu M,Moreau-Gaudry F,Guyonnet-Duperat V,Hermine O,Melo J V,Dupouy M,Turcq B,Mahon F-X,Pasquet J-M
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference45 articles.
1. Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A . Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993; 82: 3524–3529.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.
3. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–104.
4. Goldman JM . Chronic myeloid leukemia – still a few questions. Exp Hematol 2004; 32: 2–10.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献